使用氯吡格雷和普拉格雷的急性冠脉综合征出血的预测因素。 - Suppr | 超能文献

Predictors of bleeding in acute coronary syndromes with clopidogrel and prasugrel.

作者信息

Rodriguez Leandro, Conde Diego, Lalor Nicolas, Elissamburu Pablo, Trivi Marcelo

出版信息

Am J Emerg Med. 2013 Aug;31(8):1287. doi: 10.1016/j.ajem.2013.05.025. Epub 2013 Jun 14.

DOI:10.1016/j.ajem.2013.05.025

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Predictors of bleeding in acute coronary syndromes with clopidogrel and prasugrel.使用氯吡格雷和普拉格雷的急性冠脉综合征出血的预测因素。

Am J Emerg Med. 2013 Aug;31(8):1287. doi: 10.1016/j.ajem.2013.05.025. Epub 2013 Jun 14.

2

Predictors of myocardial infarction after an acute coronary syndrome with clopidogrel and prasugrel.急性冠状动脉综合征使用氯吡格雷和普拉格雷后心肌梗死的预测因素

Am J Emerg Med. 2013 Aug;31(8):1287-8. doi: 10.1016/j.ajem.2013.05.037. Epub 2013 Jun 24.

3

Prasugrel for acute coronary syndromes: faster, more potent, but higher bleeding risk.普拉格雷治疗急性冠脉综合征：更快、更强效，但出血风险更高。

Cleve Clin J Med. 2009 Dec;76(12):707-14. doi: 10.3949/ccjm.76a.09116.

4

Prasugrel: Clinical development and therapeutic application.普拉格雷：临床开发与治疗应用。

Adv Ther. 2009 Nov;26(11):999-1011. doi: 10.1007/s12325-009-0081-y. Epub 2009 Dec 17.

5

Will prasugrel supersede clopidogrel for acute coronary syndromes?普拉格雷会取代氯吡格雷用于急性冠脉综合征吗？

Med J Aust. 2008 Apr 7;188(7):381-2. doi: 10.5694/j.1326-5377.2008.tb01678.x.

6

Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials.普拉格雷与氯吡格雷在急性冠脉综合征患者中的疗效及安全性比较：TRITON-TIMI 38试验结果

Expert Rev Cardiovasc Ther. 2009 Jan;7(1):17-23. doi: 10.1586/14779072.7.1.17.

7

[Prasugrel for acute and long-term treatment of patients with acute coronary syndromes: what is state-of-the-art?].[普拉格雷用于急性冠状动脉综合征患者的急性和长期治疗：当前的最佳治疗方法是什么？]

Dtsch Med Wochenschr. 2011 Apr;136(15):782-5. doi: 10.1055/s-0031-1272567. Epub 2011 Mar 22.

8

Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis.普拉格雷对接受经皮冠状动脉介入治疗的急性冠脉综合征患者的早期和晚期获益：TRITON-TIMI 38（通过普拉格雷优化血小板抑制评估治疗转归改善的试验-心肌梗死溶栓38）分析

J Am Coll Cardiol. 2008 May 27;51(21):2028-33. doi: 10.1016/j.jacc.2008.04.002.

9

Prasugrel: a guide to its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention in the US.普拉格雷：在美国经皮冠状动脉介入治疗的急性冠状动脉综合征患者中的应用指南。

Am J Cardiovasc Drugs. 2012 Jun 1;12(3):207-16. doi: 10.2165/11209640-000000000-00000.

10

Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.普拉格雷：新药。血管成形术和支架置入术后：继续使用阿司匹林+氯吡格雷。

Prescrire Int. 2009 Oct;18(103):193-5.

引用本文的文献

1

Evaluation of Tolerability, Pharmacokinetics and Pharmacodynamics of Vicagrel, a Novel P2Y12 Antagonist, in Healthy Chinese Volunteers.新型P2Y12拮抗剂维卡格雷在健康中国志愿者中的耐受性、药代动力学和药效学评价。

Front Pharmacol. 2018 Jun 20;9:643. doi: 10.3389/fphar.2018.00643. eCollection 2018.

2

Species Comparison of Pre-systemic Bioactivation of Vicagrel, a New Acetate Derivative of Clopidogrel.氯吡格雷新乙酸衍生物维卡格雷的系统前生物活化的物种比较

Front Pharmacol. 2016 Oct 7;7:366. doi: 10.3389/fphar.2016.00366. eCollection 2016.